ClinicalTrials.gg

Program

ofirnoflast

Also written as “HT-6184” and “Ofirnoflast”.

Its studies are mostly in Myelodysplastic Syndromes · Diabetes Mellitus, Type 2 · Pain, led by Halia Therapeutics.

Furthest: phase 2, since Jan 15, 20245 company-led studies, 1 open or runningNext primary completion: Oct 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Halia Therapeutics51 open or runningphase 2since Jan 15, 2024May 19, 2022Oct 2028phase 2 · NCT07738510

Also a collaborator on its studies: parexel and tkl-research-inc.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 19, 2022First study: phase 1 study in Normal Healthy SubjectsFirst studyNCT05447546 · 64 enrolled · United States
  2. Jan 15, 2024Phase 2 study in PainNCT06241742 · 81 enrolled · United States
  3. Jun 26, 2025Phase 2 study in Myelodysplastic SyndromesNCT07052006 · 37 enrolled · India
  4. Aug 25, 2025Phase 2 study in Diabetes Mellitus, Type 2NCT07172867 · United Arab Emirates
  5. Jul 27, 2026Phase 2 study in Myelodysplastic SyndromesNCT07738510 · 70 planned · United States

Ahead

  1. Oct 2028Primary completion: phase 2 study in Myelodysplastic SyndromesNCT07738510

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07738510Myelodysplastic Syndromes · United States2Not yet recruitingOct 202870
NCT07172867Diabetes Mellitus, Type 2 · United Arab Emirates2WithdrawnJan 23, 20260
NCT07052006Myelodysplastic Syndromes · India2CompletedJan 8, 202637
NCT06241742Pain · United States2CompletedApr 30, 202481
NCT05447546Normal Healthy Subjects · United States1CompletedJul 20, 202364

How it is read

Names in the registry

  • “HT-6184”, 4 entries
  • “Ofirnoflast”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.